What one share of GH Research holds
We are a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Our initial focus is on developing our novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression, or TRD.
GH Research’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Profit | −$0.79 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.72 |
| Cash and investments | $3.97 |
| Debt | $0.00 |
| Book value | $4.51 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.01 | $0.00 | −$0.01 | — | $0.01 |
| 2020 | — | −$0.02 | $0.00 | −$0.01 | — | $0.20 |
| 2021 | — | −$0.21 | $0.00 | −$0.35 | — | $5.33 |
| 2022 | — | −$0.43 | $0.00 | −$0.50 | — | $4.80 |
| 2023 | — | −$0.68 | $0.00 | −$0.64 | — | $4.21 |
| 2024 | — | −$0.75 | $0.00 | −$0.81 | — | $3.44 |
| 2025 | — | −$0.79 | $0.00 | −$0.72 | — | $4.51 |
Common questions about GH Research
How much does one share of GH Research earn?
Over its latest fiscal year, GH Research lost $0.79 for each share.
Does GH Research pay a dividend?
GH Research didn’t pay a dividend over its latest fiscal year, according to its SEC filings.
What is GH Research’s book value per share?
GH Research’s book value is $4.51 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of December 31, 2025.
How much cash and debt does each share of GH Research have?
Each share of GH Research has $3.97 of cash and investments and $0.00 of debt, as of December 31, 2025.
What is GH Research’s free cash flow per share?
−$0.72 per share over its latest fiscal year. Free cash flow is the cash left over after spending on buildings and equipment.
Has GH Research bought back shares?
GH Research’s share count rose about 118% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.